Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Exelixis (Nasdaq: EXEL) announced its Q2 2024 financial results, reporting total revenues of $637.2 million, up from $469.8 million in Q2 2023. Net product revenues from the cabozantinib franchise reached $437.6 million, with a GAAP diluted EPS of $0.77 and non-GAAP diluted EPS of $0.84.
The FDA accepted a supplemental new drug application (sNDA) for cabozantinib in advanced neuroendocrine tumors (NET), targeting a review date of April 3, 2025. Exelixis also announced a $150 million milestone payment from Ipsen and completed a $450 million stock repurchase program. An additional $500 million stock repurchase program is planned through the end of 2025.
Operating expenses showed a decrease in R&D and SG&A, leading to a GAAP net income of $226.1 million compared to $81.2 million in Q2 2023. Exelixis also highlighted updated clinical developments including the completion of the phase 3 CONTACT-02 study in metastatic castration-resistant prostate cancer.
Exelixis (Nasdaq: EXEL) ha annunciato i risultati finanziari per il secondo trimestre del 2024, riportando ricavi totali di 637,2 milioni di dollari, rispetto ai 469,8 milioni di dollari nel secondo trimestre del 2023. I ricavi netti dei prodotti della franchigia cabozantinib hanno raggiunto i 437,6 milioni di dollari, con un utile per azione (EPS) diluito GAAP di 0,77 dollari e un EPS diluito non GAAP di 0,84 dollari.
La FDA ha accettato una domanda supplementare per un nuovo farmaco (sNDA) per cabozantinib nel trattamento dei tumori neuroendocrini avanzati (NET), con una data di revisione prevista per il 3 aprile 2025. Exelixis ha anche annunciato un pagamento di traguardo di 150 milioni di dollari da Ipsen e ha completato un programma di riacquisto di azioni da 450 milioni di dollari. Un ulteriore programma di riacquisto di azioni da 500 milioni di dollari è previsto fino alla fine del 2025.
Le spese operative hanno mostrato una diminuzione nelle spese di ricerca e sviluppo e nelle spese generali e amministrative, portando a un reddito netto GAAP di 226,1 milioni di dollari rispetto agli 81,2 milioni di dollari del secondo trimestre del 2023. Exelixis ha anche messo in evidenza gli sviluppi clinici aggiornati, compresa la conclusione dello studio di fase 3 CONTACT-02 nel cancro della prostata resistente alla castrazione in stadio metastatico.
Exelixis (Nasdaq: EXEL) anunció sus resultados financieros del segundo trimestre de 2024, reportando ingresos totales de 637,2 millones de dólares, en comparación con 469,8 millones de dólares en el segundo trimestre de 2023. Los ingresos netos por productos de la franquicia cabozantinib alcanzaron los 437,6 millones de dólares, con una ganancia por acción (EPS) diluida GAAP de 0,77 dólares y una EPS diluida no GAAP de 0,84 dólares.
La FDA aceptó una solicitud suplementaria de nuevo medicamento (sNDA) para cabozantinib en tumores neuroendocrinos avanzados (NET), con una fecha de revisión programada para el 3 de abril de 2025. Exelixis también anunció un pago de hito de 150 millones de dólares de Ipsen y completó un programa de recompra de acciones de 450 millones de dólares. Se planea un programa adicional de recompra de acciones de 500 millones de dólares hasta finales de 2025.
Los gastos operativos mostraron una disminución en I+D y SG&A, lo que resultó en un ingreso neto GAAP de 226,1 millones de dólares en comparación con 81,2 millones de dólares en el segundo trimestre de 2023. Exelixis también destacó desarrollos clínicos actualizados, incluida la finalización del estudio de fase 3 CONTACT-02 en cáncer de próstata resistente a la castración metastásico.
Exelixis (Nasdaq: EXEL)는 2024년 2분기 재무 결과를 발표하며 총 수익이 6억 3,720만 달러에 달하고, 이는 2023년 2분기의 4억 6,980만 달러에서 증가한 수치입니다. 카보잔티닙 프랜차이즈의 순 제품 수익은 4억 3,760만 달러에 달하며, GAAP 기준 희석 주당 순이익(EPS)은 0.77 달러, 비 GAAP 기준 희석 EPS는 0.84 달러입니다.
FDA는 고급 신경내분비 종양(NET) 치료를 위한 카보잔티닙의 보충 신약 허가 신청(sNDA)을 수락하였으며, 검토 날짜는 2025년 4월 3일로 예정되어 있습니다. Exelixis는 Ipsen으로부터 1억 5천만 달러의 이정표 지급을 발표하였고, 4억 5천만 달러 규모의 자사주 매입 프로그램을 완료하였습니다. 2025년 말까지 5억 달러 규모의 추가 자사주 매입 프로그램이 계획되어 있습니다.
운영 비용은 연구개발(R&D) 및 판매관리비(SG&A)에서 감소를 보여, GAAP 기준 순이익은 2억 2천 610만 달러를 기록하였으며, 이는 2023년 2분기의 8천 120만 달러와 비교됩니다. Exelixis는 전이성 거세 저항성 전립선암에서 3상 CONTACT-02 연구의 완료를 포함하여, 업데이트된 임상 개발 사항도 강조하였습니다.
Exelixis (Nasdaq: EXEL) a annoncé ses résultats financiers pour le deuxième trimestre de 2024, rapportant des revenus totaux de 637,2 millions de dollars, en hausse par rapport à 469,8 millions de dollars au deuxième trimestre de 2023. Les revenus nets des produits de la franchise cabozantinib ont atteint 437,6 millions de dollars, avec un BPA dilué GAAP de 0,77 dollar et un BPA dilué non GAAP de 0,84 dollar.
La FDA a accepté une demande d'autorisation de médicament supplémentaire (sNDA) pour le cabozantinib dans le traitement des tumeurs neuroendocrines avancées (NET), avec une date d'examen prévue pour le 3 avril 2025. Exelixis a également annoncé un paiement d'étape de 150 millions de dollars de la part d'Ipsen et a complété un programme de rachat d'actions de 450 millions de dollars. Un programme de rachat d'actions supplémentaire de 500 millions de dollars est prévu jusqu'à la fin de 2025.
Les dépenses opérationnelles ont montré une diminution des dépenses de R&D et des SG&A, conduisant à un revenu net GAAP de 226,1 millions de dollars par rapport à 81,2 millions de dollars au deuxième trimestre de 2023. Exelixis a également mis en avant les développements cliniques mis à jour, y compris l'achèvement de l'étude de phase 3 CONTACT-02 dans le cancer de la prostate résistant à la castration métastatique.
Exelixis (Nasdaq: EXEL) hat die finanziellen Ergebnisse für das 2. Quartal 2024 bekannt gegeben und berichtet von Gesamterlösen in Höhe von 637,2 Millionen Dollar, im Vergleich zu 469,8 Millionen Dollar im 2. Quartal 2023. Die Netto-Produkteinnahmen aus der Cabozantinib-Franchise betrugen 437,6 Millionen Dollar, mit einem GAAP verwässerten EPS von 0,77 Dollar und einem non-GAAP verwässerten EPS von 0,84 Dollar.
Die FDA hat einen ergänzenden Antrag auf Zulassung eines neuen Medikaments (sNDA) für Cabozantinib bei fortgeschrittenen neuroendokrinen Tumoren (NET) akzeptiert und ein Prüfdatum für den 3. April 2025 festgelegt. Exelixis gab außerdem eine Meilensteinzahlung von 150 Millionen Dollar von Ipsen bekannt und schloss ein Aktienrückkaufprogramm im Wert von 450 Millionen Dollar ab. Ein zusätzliches Aktienrückkaufprogramm über 500 Millionen Dollar ist bis Ende 2025 geplant.
Die Betriebskosten zeigten einen Rückgang in Forschung und Entwicklung sowie in Verwaltungskosten, was zu einem GAAP-Nettoeinkommen von 226,1 Millionen Dollar im Vergleich zu 81,2 Millionen Dollar im 2. Quartal 2023 führte. Exelixis hob auch aktualisierte klinische Entwicklungen hervor, einschließlich des Abschlusses der Phase-3-Studie CONTACT-02 bei metastasiertem kastrationsresistentem Prostatakrebs.
- Total revenues increased to $637.2 million, a significant rise from $469.8 million in Q2 2023.
- Net product revenues from the cabozantinib franchise reached $437.6 million.
- GAAP diluted EPS rose to $0.77, with non-GAAP diluted EPS at $0.84.
- FDA accepted the sNDA for cabozantinib in advanced NET with a target action date of April 3, 2025.
- Earned a $150 million milestone payment from Ipsen.
- Completed a $450 million stock repurchase program for 2024.
- Announced a new $500 million stock repurchase program through the end of 2025.
- R&D expenses decreased to $211.1 million from $232.6 million, and SG&A expenses decreased to $132 million from $141.7 million.
- Provision for income taxes increased to $66.7 million from $19.2 million in Q2 2023.
- Final overall survival in the CONTACT-02 trial did not achieve statistical significance.
Insights
Exelixis has delivered a strong Q2 2024 performance, with total revenues of
The company's profitability has improved substantially, with GAAP net income of
Exelixis' financial guidance for 2024 remains robust, with total revenues projected between
The FDA's acceptance of Exelixis' sNDA for cabozantinib in advanced neuroendocrine tumors (NET) is a significant milestone. With a PDUFA date of April 3, 2025, this could potentially expand cabozantinib's indications, addressing a high unmet medical need in NET patients.
The completion of the final overall survival analysis for the CONTACT-02 trial in metastatic castration-resistant prostate cancer (mCRPC) is crucial. While it didn't achieve statistical significance, the continued favorable trend and the previously reported significant progression-free survival benefit could still support an sNDA submission this year.
The initiation of the XB010 phase 1 trial and the planned STELLAR-311 phase 3 trial for zanzalintinib in NET demonstrate Exelixis' commitment to expanding its oncology pipeline. However, the discontinuation of XB002 development highlights the challenges in drug development and the importance of portfolio prioritization.
Exelixis' market position in oncology continues to strengthen, driven by the expanding indications for cabozantinib. The potential entry into the NET market could open up new revenue streams, especially given the orphan drug designation for pancreatic NET.
The collaboration with Ipsen is proving fruitful, as evidenced by the
The company's focus on next-generation medicines, including antibody-drug conjugates like XB010, aligns with current trends in oncology drug development. However, the competitive landscape in areas like tissue factor-targeting ADCs necessitates careful portfolio management, as seen with the XB002 discontinuation.
Exelixis' continued share repurchase programs, totaling
- Total Revenues of
- GAAP Diluted EPS of
-
- Earned
- Completed
- Announced Additional Stock Repurchase Program for up to
- Conference Call and Webcast Today at 5:00 PM Eastern Time -
“Exelixis is well positioned for an impactful second half of 2024 as we continue to grow the cabozantinib franchise, execute on our regulatory and development objectives, and advance our next-generation pipeline,” said Michael M. Morrissey, Ph.D., President and CEO, Exelixis. “Cabozantinib’s second quarter commercial performance was strong both in the
Second Quarter 2024 Financial Results
Total revenues for the quarter ended June 30, 2024 were
Total revenues for the quarter ended June 30, 2024 included net product revenues of
Collaboration revenues, composed of license revenues and collaboration services revenues, were
Research and development expenses for the quarter ended June 30, 2024 were
Selling, general and administrative expenses for the quarter ended June 30, 2024 were
Provision for income taxes for the quarter ended June 30, 2024 was
GAAP net income for the quarter ended June 30, 2024 was
Non-GAAP net income for the quarter ended June 30, 2024 was
Non-GAAP Financial Measures
To supplement Exelixis’ financial results presented in accordance with
Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Exelixis’ results from period to period, and to identify operating trends in Exelixis’ business. Exelixis has excluded stock-based compensation expense, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.
These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis’ business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.
2024 Financial Guidance
Exelixis is providing the following updated financial guidance for fiscal year 2024 (1):
Total revenues |
|
|
Net product revenues (2) |
|
|
Cost of goods sold |
|
|
Research and development expenses (3) |
|
|
Selling, general and administrative expenses (4) |
|
|
Effective tax rate |
|
|
____________________ (1) 2024 financial guidance excludes expenses related to the restructuring plan announced in January 2024.
(2) Exelixis’ 2024 net product revenues guidance range includes the impact of a
(3) Includes
(4) Includes |
||
Cabozantinib and Pipeline Highlights
Cabozantinib Franchise Net Product Revenues and Royalties. Net product revenues generated by the cabozantinib franchise in the
Achievement of Cabozantinib Sales-Based Milestone from Ipsen. Today, Exelixis announced it earned and recognized in license revenues a
FDA Accepts for Standard Review the sNDA for Cabozantinib for Patients with Advanced NET; Updated Results from Phase 3 CABINET Study to be Presented during an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024. Today, Exelixis announced that the FDA accepted its sNDA for cabozantinib for patients with previously treated advanced pancreatic NET (pNET), and for patients with previously treated advanced extra-pancreatic NET (epNET). The FDA assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. The FDA also granted orphan drug designation to cabozantinib for the treatment of pNET. The application was based on results from the phase 3 CABINET trial, which evaluated cabozantinib compared with placebo in patients with previously treated pNET and epNET. The CABINET study is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the NCI-funded Alliance for Clinical Trials in Oncology. Updated results from CABINET, including final results on the primary efficacy endpoint of progression-free survival by Blinded Independent Central Review, will be presented during the ESMO Congress 2024 in September.
Exelixis Partner Ipsen Opts into Phase 3 CABINET Pivotal Trial in Advanced NET. In July, Ipsen announced it opted into the phase 3 CABINET pivotal trial, expanding the existing collaboration and license agreement with Exelixis and permitting Ipsen to seek potential marketing authorizations for CABOMETYX in advanced pNET and epNET from regulatory authorities outside of the
Phase 3 CONTACT-02 Metastatic Castration-Resistant Prostate Cancer (mCRPC) Study Update and Intention to Submit sNDA in 2024. Today, Exelixis announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed. This study is evaluating cabozantinib in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with mCRPC and measurable soft-tissue disease who have progressed after treatment with one prior NHT. As previously reported, the CONTACT-02 study met one of its two primary endpoints, demonstrating a statistically significant benefit in progression-free survival (PFS) (hazard ratio: 0.65;
Enrollment Completion for Zanzalintinib Phase 3 STELLAR-303 Study and Announcement of New Pivotal Trial for Zanzalintinib in Neuroendocrine Tumors. Today, Exelixis announced that enrollment has been completed in the STELLAR-303 phase 3 pivotal study. STELLAR-303 is evaluating zanzalintinib in combination with atezolizumab compared with regorafenib in patients with metastatic refractory colorectal cancer that is not microsatellite instability-high or mismatch repair-deficient. The primary endpoint in the study is OS in the patients without liver metastases. Exelixis anticipates preliminary results from the study to readout in 2025. Additionally, Exelixis intends to initiate a new phase 3 pivotal trial, STELLAR-311, evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with pNET and epNET, in the first half of 2025.
Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors. Today, Exelixis announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial of XB010 in patients with locally advanced or metastatic solid tumors. XB010, an antibody-drug conjugate (ADC) consisting of a monomethyl auristatin E payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4, is the first custom ADC generated through Exelixis’ biotherapeutics collaboration network. The dose-escalation stage of this phase 1, global, open-label study will evaluate XB010 as a single agent and in combination with pembrolizumab to inform the cohort-expansion stage. The expansion cohorts are designed to further assess the tolerability and activity of monotherapy and of the combination in specific indications.
Portfolio Prioritization Update. Today, Exelixis announced it will discontinue the development of XB002, the company’s tissue factor (TF)-targeting ADC, as part of its portfolio prioritization efforts. Based on available data, the compound is unlikely to improve upon tisotumab vedotin or other competitor TF-targeting ADCs currently in development. The company plans to disclose data from the phase 1 JEWEL-101 study, evaluating XB002 in advanced solid tumors, at a later date. Preclinical development of XB371, its ADC consisting of a topoisomerase payload conjugated to a TF-targeting monoclonal antibody, is ongoing. Exelixis plans to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and its growing pipeline.
Corporate Highlights
Settlement of CABOMETYX Patent Litigation with Cipla Limited and Cipla
Completion of the
Announcement of Additional Stock Repurchase Program for up to
Basis of Presentation
Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31. For convenience, references in this press release as of and for the fiscal periods ended June 28, 2024 are indicated as being as of and for the periods ended June 30, 2024.
Conference Call and Webcast
Exelixis management will discuss the company’s financial results for the second quarter of 2024 and provide a general business update during a conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT today, Tuesday, August 6, 2024.
To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.
About Exelixis
Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis’ belief that it is well-positioned for an impactful second half of 2024; the regulatory review process with respect to Exelixis’ sNDA for cabozantinib in advanced NET, including the PDUFA target action date assigned by the FDA, and the potential to bring cabozantinib as a new treatment option for these patients with high unmet medical need; Exelixis’ plans to reallocate resources to new pivotal trials in zanzalintinib and to advancing phase 1 efforts for XL309 and XB010, as well as to the rest of the company’s growing pipeline; Exelixis’ updated 2024 financial guidance; the anticipated timing for receipt of a
Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.
EXELIXIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share amounts) (unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
Revenues: |
|
|
|
|
|
|
|
||||||||
Net product revenues |
$ |
437,581 |
|
|
$ |
409,646 |
|
|
$ |
816,104 |
|
|
$ |
773,046 |
|
License revenues |
|
194,986 |
|
|
|
52,747 |
|
|
|
239,662 |
|
|
|
91,039 |
|
Collaboration services revenues |
|
4,611 |
|
|
|
7,455 |
|
|
|
6,638 |
|
|
|
14,551 |
|
Total revenues |
|
637,178 |
|
|
|
469,848 |
|
|
|
1,062,404 |
|
|
|
878,636 |
|
Operating expenses: |
|
|
|
|
|
|
|
||||||||
Cost of goods sold |
|
17,667 |
|
|
|
17,705 |
|
|
|
38,923 |
|
|
|
32,020 |
|
Research and development |
|
211,147 |
|
|
|
232,570 |
|
|
|
438,836 |
|
|
|
466,816 |
|
Selling, general and administrative |
|
132,015 |
|
|
|
141,723 |
|
|
|
245,999 |
|
|
|
273,120 |
|
Restructuring |
|
475 |
|
|
|
— |
|
|
|
33,310 |
|
|
|
— |
|
Total operating expenses |
|
361,304 |
|
|
|
391,998 |
|
|
|
757,068 |
|
|
|
771,956 |
|
Income from operations |
|
275,874 |
|
|
|
77,850 |
|
|
|
305,336 |
|
|
|
106,680 |
|
Interest income |
|
17,258 |
|
|
|
22,541 |
|
|
|
37,152 |
|
|
|
42,043 |
|
Other expense, net |
|
(287 |
) |
|
|
(5 |
) |
|
|
(376 |
) |
|
|
(59 |
) |
Income before income taxes |
|
292,845 |
|
|
|
100,386 |
|
|
|
342,112 |
|
|
|
148,664 |
|
Provision for income taxes |
|
66,729 |
|
|
|
19,208 |
|
|
|
78,679 |
|
|
|
27,458 |
|
Net income |
$ |
226,116 |
|
|
$ |
81,178 |
|
|
$ |
263,433 |
|
|
$ |
121,206 |
|
Net income per share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.78 |
|
|
$ |
0.25 |
|
|
$ |
0.89 |
|
|
$ |
0.37 |
|
Diluted |
$ |
0.77 |
|
|
$ |
0.25 |
|
|
$ |
0.88 |
|
|
$ |
0.37 |
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
|
289,216 |
|
|
|
324,205 |
|
|
|
294,986 |
|
|
|
324,312 |
|
Diluted |
|
293,974 |
|
|
|
327,305 |
|
|
|
299,752 |
|
|
|
326,792 |
|
EXELIXIS, INC. RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME (in thousands, except per share amounts) (unaudited) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||||||
|
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
GAAP net income |
$ |
226,116 |
|
|
$ |
81,178 |
|
|
$ |
263,433 |
|
|
$ |
121,206 |
|
Adjustments: |
|
|
|
|
|
|
|
||||||||
Stock-based compensation - research and development expenses (1) |
|
9,178 |
|
|
|
9,589 |
|
|
|
13,070 |
|
|
|
12,841 |
|
Stock-based compensation - selling, general and administrative expenses (1) |
|
16,176 |
|
|
|
15,311 |
|
|
|
31,397 |
|
|
|
28,720 |
|
Income tax effect of the above adjustments |
|
(5,841 |
) |
|
|
(5,781 |
) |
|
|
(10,289 |
) |
|
|
(9,642 |
) |
Non-GAAP net income |
$ |
245,629 |
|
|
$ |
100,297 |
|
|
$ |
297,611 |
|
|
$ |
153,125 |
|
GAAP net income per share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.78 |
|
|
$ |
0.25 |
|
|
$ |
0.89 |
|
|
$ |
0.37 |
|
Diluted |
$ |
0.77 |
|
|
$ |
0.25 |
|
|
$ |
0.88 |
|
|
$ |
0.37 |
|
Non-GAAP net income per share: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
0.85 |
|
|
$ |
0.31 |
|
|
$ |
1.01 |
|
|
$ |
0.47 |
|
Diluted |
$ |
0.84 |
|
|
$ |
0.31 |
|
|
$ |
0.99 |
|
|
$ |
0.47 |
|
Weighted-average common shares outstanding: |
|
|
|
|
|
|
|
||||||||
Basic |
|
289,216 |
|
|
|
324,205 |
|
|
|
294,986 |
|
|
|
324,312 |
|
Diluted |
|
293,974 |
|
|
|
327,305 |
|
|
|
299,752 |
|
|
|
326,792 |
|
____________________ (1) Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, Compensation—Stock Compensation. |
|||||||||||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806336755/en/
Chris Senner
Chief Financial Officer
Exelixis, Inc.
650-837-7240
csenner@exelixis.com
Susan Hubbard
EVP, Public Affairs & Investor Relations
Exelixis, Inc.
650-837-8194
shubbard@exelixis.com
Source: Exelixis, Inc.
FAQ
What were Exelixis' revenues for Q2 2024?
How did Exelixis' cabozantinib franchise perform in Q2 2024?
What was Exelixis' GAAP diluted EPS for Q2 2024?
When is the FDA's target action date for cabozantinib's sNDA in advanced NET?
How much is Exelixis' new stock repurchase program?
What milestone payment did Exelixis earn from Ipsen?
